Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aushon BioSystems names new VP of North American sales
Mr Schmeizl will be responsible for developing and leading the North American sales team, including oversight of sales operations, processes and training. Mr Schmeizl brings to Aushon more
Mr Schmeizl will be responsible for developing and leading the North American sales team, including oversight of sales operations, processes and training. Mr Schmeizl brings to Aushon more
Mr LaPorte was recently retired as senior vice president of business development and general counsel from the company. Prior to Invacare, Mr LaPorte was a partner at Calfee,
In his new role, Dr Moerck will lead Valensa’s move into the next generation of high-performance plant-derived dietary supplements and functional food ingredients, which includes Valensa’s ‘direct to
Mr Weaver is primarily responsible for management of the financial operations of the company. Most recently, Mr Weaver served as CFO of Talyst, a pharmacy automation healthcare IT
The biologics pilot plant will allow UCB to further optimize the bio-manufacturing processes for its biological compounds under development, extending its knowledge and competencies in this field. This
Previously, Mr Williams was a founding member of the Partnership for Prevention, an organization of public and private sector representatives who focus on preventive healthcare policies. Mr Williams
Dr Henderson joins the Cytokinetics board of directors with over 30 years of experience in the life science industry. Since December 2000, Dr Henderson has served as a
The Phase I trial has been designed to compare pharmacokinetics in Parkinson’s patients of two formulations of DM-1992 and a generic version of Sinemet CR, a commercially available
Following the promising results generated in the frame of the initial collaboration established between Flamel and Merck Serono in 2007, Merck Serono has made the decision to exercise
These offices comprise more than 80% of Gentiva’s current pediatric care operations. Terms have not been disclosed. According to Gentiva, the transaction fits with its stated objective of